The xenotransplantation hybrid hospital: structural, economic, and regulatory frameworks for zero-ischemia clinical translation

Xenotransplantation using genetically engineered porcine organs offers a solution to the global organ shortage. However, the extreme vulnerability of porcine xenografts to ischemia-reperfusion injury (IRI) poses a barrier that conventional transplant infrastructure cannot overcome. We evaluated the architectural, biological, economic, and regulatory frameworks of a xenotransplantation hybrid hospital (integrating donor swine procurement suites with human operating theaters) as a structural solution to xenogeneic IRI. We systematically reviewed evidence on interspecies molecular incompatibilities amplifying IRI, machine perfusion platforms, dual-track architectural biosafety, health economic modeling, and regulatory prerequisites. Interspecies incompatibilities involving thrombomodulin, tissue factor pathway inhibitor, von Willebrand factor-platelet glycoprotein Ib, CD73, and CD39 amplify xenogeneic IRI, yielding initial xenograft dysfunction rates up to 60% with cold storage versus 0% with perfusion. The hybrid hospital eradicates ischemia via structural colocation, dual-track ventilation separation, and airtight sterile transfer barriers. This framework complements genetic modification and perfusion. Break-even analysis projects parity with mobile perfusion models within 2 to 4 years at 30 to 60 annual procedures ($45,000-$80,000 per quality-adjusted life-year). Regulatory implementation requires dedicated legislation, 50-year biospecimen archives, and blockchain-based lifelong surveillance. The xenotransplantation hybrid hospital is a clinical necessity and an economic imperative, providing the foundation to overcome xenogeneic IRI and scale xenotransplantation safely.